About BMRT
BMRT is a Healthcare company based in Palm City (United States) founded in 2023 by Lee Duke and Bo Short. It operates as a cancer diagnosis devices based on molecular detection are provided. BMRT has raised $3.06 million across 1 funding round. Its chief executive is Bo Short. BMRT offers products and services including Detection Technology and Environmental Monitoring. Its focus areas include Life Sciences, Oncology, Medical Devices and Imaging. Its legal entity is Base Molecular Resonance Technologies, LLC. Its competitors include Scholar Rock, Fluxion Biosciences, Ionpath, SamanTree Medical and Phase Focus and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
BMRT was founded in 2023 in Palm City, United States, as a provider of medical devices in the healthcare sector. Devices are designed to detect elements, molecules, or substances through their molecular structure. Cancer identification is enabled on laboratory slides and within human subjects. Operations focus on diagnostic tools for oncology applications.
- Headquarters Palm City, United States
- Founders Lee Duke, Bo Short
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bmrt.io
- Legal Name Base Molecular Resonance Technologies, Llc
- Total Equity Funding$3.06M (USD)
in 1 rounds
- Latest Funding Round$3.06M (USD), Series A
Nov 2023
Products & Services of BMRT
BMRT offers a comprehensive portfolio of products and services, including Detection Technology and Environmental Monitoring.
System for detecting elements and diseases via subatomic interactions.
Technology for assessing air, water, and hazardous waste quality.
Funding Insights of BMRT
BMRT has successfully raised a total of $3.06M through 1 strategic funding round. The most recent funding activity was a Series A round of $3.06 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.06M
- Total Rounds 1
- Last Round Series A — $3.06M
- First Round $3.06M
(Nov 2023)
All 1 funding rounds of BMRT with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $3.06M | Series A | – | – | – |
People of BMRT
4 people are tracked at BMRT (3 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Lee Duke | Co-Founder | Leadership |
Bo Short | Co-Founder & CEO | Leadership |
Adam Jarvis | Senior Vice President, Government & Defense Programs | Leadership |
Kenneth Valentine | Advisory Board | Board & advisors |
Complete people profiles for BMRT
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BMRT
2 dated milestones of BMRT, from founding to its latest funding, stage changes and deals.
- Founded BMRT is founded.
- Funding First funding round of $3.1M.
Competitors of BMRT
BMRT has 10 listed competitors in our database, 9 of them funded. They include Scholar Rock, Fluxion Biosciences, Ionpath, SamanTree Medical and Phase Focus, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| scholarrock.com | 2012 | Cambridge, United States | $103.3M | 150 | Antibody-based drugs for primary myopathies are developed and targeted. | |
| fluxionbio.com | 2005 | San Francisco, United States | $20.85M | – | Microfluidics-based tools for cellular analysis are provided. | |
| ionpath.com | 2014 | Menlo Park, United States | $18M | 37 | Multiplexed ion beam imaging platform for tissue biopsies is developed. | |
| samantree.com | 2014 | Lausanne, Switzerland | $33.78M | – | A surgical digital microscope for tumor resection is developed. | |
| phasefocus.com | 2006 | Sheffield, United Kingdom | $12.08M | 10 | Provider of virtual lens that generates High definition images without high-quality lenses | |
| perfinthealthcare.com | 2005 | Chennai, India | $41.48M | 36 | Solutions for image-guided interventional procedures are developed. | |
| lightpointmedical.com | 2012 | Rickmansworth, United Kingdom | $25.33M | 19 | Intraoperative imaging devices for real-time cancer detection are developed. | |
| sascan.in | 2015 | Thiruvananthapuram, India | $339,498 | – | Cancer screening devices are developed using biophotonics technologies. | |
| sysmex.co.jp | 1968 | Hyogo, Japan | – | – | Developer of diagnostic instruments, reagents, and related software | |
| nanovery.co.uk | 2018 | London, United Kingdom | $2.12M | 1 | Nanobots are developed for cancer diagnosis through bloodstream administration. |
Detailed competitors of BMRT
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BMRT
The website of BMRT (bmrt.io) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 2.3% vs previous month
Top companies in Oncology
10 companies that operate in the same segment as BMRT (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bmrt
Complete news archive for BMRT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BMRT
BMRT was founded in 2023.
BMRT is headquartered in Palm City, United States. It is registered at Palm City, Florida, United States.
Bo Short is the current CEO of BMRT. They have also founded this company.
BMRT is a funded company, having raised a total of $3.06M across 1 funding round to date. The company's 1st funding round was a Series A of $3.06M, raised on Nov 2023.
BMRT was founded in 2023 in Palm City, United States, as a provider of medical devices in the healthcare sector. Devices are designed to detect elements, molecules, or substances through their molecular structure. Cancer identification is enabled on laboratory slides and within human subjects. Operations focus on diagnostic tools for oncology applications.
BMRT's top competitors include Scholar Rock, Ionpath and SamanTree Medical.
BMRT offers Detection Technology and Environmental Monitoring.
BMRT operates through Base Molecular Resonance Technologies, Llc.